Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with moderately severe or severe congenital haemophilia B with a factor IX activity of 2% or below according to medical records~* History of at least 150 exposure days to other factor IX products~* Patients currently treated on-demand with at least 6 bleeding episodes during the last 12 months or at least 3 bleeding episodes during the last 6 months, or patients currently on prophylaxis~Exclusion Criteria:~* Known history of factor IX inhibitors based on existing medical records, laboratory report reviews and patient and legally acceptable representative (LAR) interviews~* HIV (Human immunodeficiency virus) positive, with a viral load equal to or above 400,000 copies/mL and/or CD4+ lymphocyte count equal to or below 200/microL~* Congenital or acquired coagulation disorders other than haemophilia B~* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)~* Immune modulating or chemotherapeutic medication

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis, high dose (trial duration 52 weeks) (Type: EXPERIMENTAL): None
- Prophylaxis, low dose (trial duration 52 weeks) (Type: EXPERIMENTAL): None
- On-demand (trial duration 28 weeks) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).